What gonadorelin is, why no human version is sold in the US, what the evidence shows for fertility and TRT, and how it compares with hCG and enclomiphene.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
Gonadorelin is a lab-made copy of GnRH (gonadotropin-releasing hormone), the 10-amino-acid signal your brain uses to tell the pituitary gland to release LH and FSH. Those two hormones drive testosterone production and sperm production in men, and ovulation in women.
It used to be an FDA-approved human drug. It isn't sold as one now. Factrel (approved 1982) and Lutrepulse (approved 1989) are both listed as discontinued at the FDA. The gonadorelin products with current US labels are veterinary, for cattle.
The timing matters more than the amount. Short pulses of GnRH switch the pituitary on. A constant supply switches it off. That finding, from 1978, is the whole reason gonadorelin was given by pump in fertility medicine.
The best human evidence is in fertility, not TRT. Pulsatile GnRH restored sperm production in men born without their own GnRH signal, and ovulation in women with hypothalamic amenorrhea.
For men on testosterone therapy, the evidence is missing. We found no published trial, and no registered one, testing gonadorelin to protect fertility during TRT. The option with published data in that setting is hCG.
Status in 2026: gonadorelin is not on the HHS list of peptides covered by the October 30, 2026 compounding policy. If a clinic offers it, ask which pharmacy compounds it and under what authority.
This PeptIQ.io guide was written on November 12, 2026 from FDA databases, DailyMed labels, PubMed and ClinicalTrials.gov. It contains no dosing information.
Talk to a licensed clinician before using gonadorelin or changing anything about testosterone therapy, especially if you want children in the future.
What Is Gonadorelin?
Start with the hormone it copies. Deep in the brain, the hypothalamus releases GnRH in short bursts. Each burst reaches the pituitary gland, which answers by releasing two hormones into the blood:
LH (luteinizing hormone) tells the testes to make testosterone, and triggers ovulation in women.
FSH (follicle-stimulating hormone) supports sperm production, and egg development in women.
Gonadorelin has exactly the same amino acid sequence as natural GnRH. The current FDA-approved veterinary labels describe it as a decapeptide, a peptide 10 amino acids long, with "the identical amino acid sequence as endogenous gonadorelin." That is different from drugs like leuprolide or triptorelin, which are modified versions built to last longer.
PeptIQ.io / Gonadorelin / 01
One chain, three places to push.
Gonadorelin works at the top of the chain, so it only helps if the pituitary below it can respond. Testosterone therapy turns the whole chain down through feedback.
Hypothalamus
Releases GnRH in short pulses
Gonadorelin
Same sequence as GnRH; acts here, on the pituitary's GnRH receptor
Pituitary
Answers each pulse with LH and FSH
Enclomiphene
Blocks estrogen feedback, so more LH and FSH are released
Testes / ovaries
Testosterone and sperm; ovulation
hCG
Mimics LH directly at the testes, even when the pituitary is quiet
On testosterone therapy
The brain reads “enough” and goes quiet.
LH and FSH fall, and the testes make less of their own testosterone and less sperm. Each option above tries to restart a different link.
Evidence, not marketing.Nov 2026
Sources: DailyMed gonadorelin labels (sequence identical to natural GnRH); Naelitz et al., Nat Rev Urol 2025 (PubMed 40346275); Hochu et al., Transl Androl Urol 2025 (PubMed 41522318). Simplified for education; not treatment advice.
Because gonadorelin sits at the very top of this chain, it works only if the pituitary underneath it works. It does not act on the testes directly. That is the main difference from hCG, which mimics LH and acts on the testes itself.
Why Pulses Matter: The Key Science
The single most important fact about GnRH came from a 1978 study in Science. Researchers worked with rhesus monkeys whose own GnRH signal had been removed by a brain lesion.
When the team gave GnRH once an hour, matching the natural rhythm, the pituitary started releasing LH and FSH again.
When they gave it as a constant infusion, it did not restore hormone release.
Switching animals from hourly pulses to a constant supply caused "desensitization" or "down regulation": the pituitary stopped responding.
The authors concluded the effect came from the pattern of delivery, not the amount.
PeptIQ.io / Gonadorelin / 02
Same hormone, opposite effects.
In monkeys without their own GnRH signal, the pattern of delivery decided whether the pituitary turned on or shut down. The amount did not.
Pulses
Switches on
Hourly bursts
GnRH exposure over time
Pituitary releases LH and FSH again
Constant
Switches off
Steady infusion
GnRH exposure over time
No sustained release; the pituitary desensitizes
Evidence, not marketing.Nov 2026
Source: Belchetz, Plant, Nakai, Keogh and Knobil, Science 1978 (PubMed 100883). Schematic shapes, not measured data and not a dosing schedule. Long-acting GnRH drugs such as leuprolide use the shut-off effect on purpose.
This finding cuts both ways. It is why fertility doctors gave gonadorelin through small pumps that release a pulse every so often. It is also how long-acting GnRH drugs such as leuprolide work in the opposite direction: by keeping the receptor constantly switched on, they shut the testosterone chain down, which is why they are used in prostate cancer and early puberty.
The practical takeaway is that "more GnRH" does not simply mean "more testosterone." How it is delivered can flip the effect.
What the Evidence Actually Shows
The research on gonadorelin is old, real and narrow. Here it is by use, strongest first.
PeptIQ.io / Gonadorelin / 03
Real evidence, narrow uses.
Gonadorelin's track record is in hospital testing and fertility pumps. The use most people search for has not been studied.
Pituitary stimulation test
A single test injection, then LH is measured. Long used to diagnose early puberty.
Established
Fertility in men born without GnRH
Meta-analysis of 7 studies, 420 men: pulsatile GnRH matched gonadotropins on sperm and pregnancy, with sperm appearing earlier. Not randomized.
Good
Ovulation in hypothalamic amenorrhea
Pump therapy; a 25-year cohort of 66 women saw ovulation in 96% of cycles. The US product, Lutrepulse, was discontinued.
Good
Protecting fertility on TRT
No published or registered trial found as of Nov 12, 2026. hCG is the option with direct data here.
Untested
Evidence, not marketing.Nov 2026
Sources: Akın et al. 2015 (PubMed 26197466); Seo et al. 2025 (PubMed 41207293); Wei et al., World J Mens Health 2021 (PubMed 32777865); Quaas et al., J Assist Reprod Genet 2022 (PubMed 36378460); Drugs@FDA NDA 019687; PubMed and ClinicalTrials.gov searches, Nov 12, 2026.
Testing pituitary function (established). Gonadorelin has long been used as a stimulation test: give it once, then measure how much LH the pituitary releases. A 2015 case report described it as "widely used for the diagnosis of central precocious puberty," and a 2025 paper still compared it with triptorelin for that purpose.
Restoring fertility in men with congenital hypogonadotropic hypogonadism (good, but not randomized). These men are born without a working GnRH signal, so their testes never get the message. A 2021 meta-analysis in the World Journal of Men's Health pooled seven studies with 420 patients comparing pulsatile GnRH with gonadotropin injections (hCG plus FSH-type hormones):
Pulsatile GnRH was linked to larger testes and sperm appearing about 5.3 months earlier on average.
There was no significant difference in how many men ended up with sperm, in sperm concentration, or in pregnancy rates.
Allergic reactions occurred mostly in the GnRH groups. Gynecomastia and acne were more common with gonadotropins.
The authors called for high-quality randomized trials, because the included studies were not randomized.
One of the larger studies in that analysis, a 2017 cohort of 202 men from Peking Union Medical College Hospital, found median time to first sperm of 6 months with pulsatile GnRH versus 18 months with gonadotropins. It also found lower testosterone levels in the GnRH group during follow-up.
Restoring ovulation in women with hypothalamic amenorrhea (good, observational). In a 25-year Swiss cohort of 66 women published in 2022, pulsatile GnRH by pump produced ovulation in 96% of cycles, mostly with a single follicle, and a cumulative clinical pregnancy rate of 74.4% per treatment. Lutrepulse, the US product for this use, was discontinued, and a 2018 Fertility and Sterility commentary called the approach "missing in action."
Protecting fertility in men on testosterone therapy (no direct evidence). This is the reason most people search for gonadorelin, and it is where the evidence runs out. We found no published trial on PubMed, and no registered trial on ClinicalTrials.gov, testing gonadorelin alongside testosterone to preserve sperm production (searched November 12, 2026). A 2026 Sexual Medicine Reviews paper on peptides in urology notes simply that gonadorelin "was Food and Drug Administration approved but is no longer manufactured."
Gonadorelin vs hCG vs Enclomiphene on TRT
Here is the problem all three try to solve. Testosterone therapy tells the brain there is plenty of testosterone already, so the brain turns down LH and FSH. The testes then make less of their own testosterone and less sperm. A 2025 review in Nature Reviews Urology states that exogenous testosterone is contraindicated in men trying to conceive, and the American Urological Association's 2018 guideline includes specific statements for men interested in preserving fertility.
hCG acts like LH, directly on the testes, so it works even when the brain's signal is suppressed. In a 2013 Journal of Urology study of 26 men on testosterone plus low-dose hCG, no man became azoospermic (no sperm) over a mean follow-up of 6.2 months, semen measures did not change, and 9 of the 26 contributed to a pregnancy. That was a small retrospective study without a control group, but it is direct evidence in the right population. A 2025 review in Translational Andrology and Urology says multiple studies show hCG "maintains sperm production even with full gonadotropin suppression from TRT."
Gonadorelin acts one step higher, at the pituitary. The open question is whether intermittent injections can keep LH and FSH going while testosterone therapy is pushing them down. No trial has answered that.
Enclomiphene is not a peptide. It blocks estrogen's feedback signal so the brain releases more LH and FSH. The same 2025 review describes it as increasing the body's own testosterone while maintaining sperm production. It is an alternative to testosterone therapy, rather than an add-on to it. Enclomifene.com, a physician-prescribed telehealth brand, has more on how it is prescribed.
Is Gonadorelin FDA Approved or Legal in 2026?
The short answer: it was approved for people, it no longer is on the market, and its current regulatory position is less clear than the marketing suggests.
Human products: the FDA's Drugs@FDA database lists Factrel (gonadorelin hydrochloride, NDA 018123, approved September 30, 1982) and Lutrepulse (gonadorelin acetate kit, NDA 019687, approved October 10, 1989). Both are marked discontinued.
Animal products: the gonadorelin labels currently on DailyMed are veterinary products such as Factrel Injection from Zoetis and Cystorelin. They are labeled for cattle, for ovarian cysts and breeding programs, and their labels say federal law restricts them to use by or on the order of a licensed veterinarian.
Why hCG changed but gonadorelin did not: on March 23, 2020, products like hCG (Novarel, Pregnyl and others) became regulated as biologics. The FDA said those products are no longer eligible for the compounding exemptions in sections 503A and 503B. Gonadorelin, at 10 amino acids, is far below the 40-amino-acid line that defines a protein under 21 CFR 600.3(h)(6), so it stayed a regular drug.
The October 2026 HHS policy: the enforcement discretion policy published October 30, 2026 lists six peptides in Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Gonadorelin is not one of them.
So if a clinic offers gonadorelin, the right question is not "is it legal?" but "which pharmacy compounds this, from what source, and under which section of the law?" Products sold online as "research use only" gonadorelin are not medicines and are not tested to medicine standards. Gonadorelin.org, a meds.you brand site, says it does not prescribe gonadorelin yet and is running a waitlist for physician-supervised access.
Side Effects and Safety Questions
Gonadorelin has a long history in diagnostic testing, but the safety data come mostly from short-term hospital use and fertility pumps, not from long-term self-injection.
Allergic reactions. The 2021 meta-analysis found allergic reactions mainly in the pulsatile GnRH groups. A 2015 case report described severe anaphylaxis within 3 minutes of an intravenous gonadorelin test in an 8-year-old girl, who recovered after emergency treatment. The authors advised giving it where systemic reactions can be handled.
The wrong pattern can suppress hormones. Based on the 1978 work, steady exposure desensitizes the pituitary. No study we found tells you where intermittent injections fall on that spectrum for men on testosterone therapy.
Unknown product quality. Outside a licensed pharmacy, you cannot confirm identity, purity, sterility or strength.
Questions to bring to your clinician:
Do I need to protect fertility now, or in the next few years? Should I see a urologist or fertility specialist before starting testosterone?
Would hCG or enclomiphene, which have more published evidence in my situation, be a better fit?
If you prescribe gonadorelin, which pharmacy compounds it, and can I see its certificate of analysis?
Which labs, such as LH, FSH, testosterone and a semen analysis, would show whether it is working?
What would make you advise me to stop?
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each claim in it against published research. It is useful on posts that say gonadorelin "keeps your testes working on TRT" without citing a study. Our guide to reading a certificate of analysis explains what a lab report does and does not prove. If you and your clinician decide on a plan, the PeptIQ app keeps medications, labs such as LH, FSH and testosterone, and symptoms on one timeline you can share, and PeptIQ AI answers questions against your own log rather than a forum thread.
Talk to a Licensed Clinician
Talk to a licensed clinician before using gonadorelin. If fertility matters to you, raise it before starting testosterone, not after. Sperm production can take months to recover once it is suppressed, and the options with the most evidence, hCG and stopping or avoiding testosterone, are choices a clinician should help you weigh. If you are already using a product sold as gonadorelin, tell your clinician and bring the product and its label.
Frequently Asked Questions
Q: What is gonadorelin?
A: Gonadorelin is a synthetic version of GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide made by the hypothalamus. It signals the pituitary to release LH and FSH, which drive testosterone production, sperm production and ovulation. It has the same sequence as the natural hormone.
Q: Is gonadorelin FDA approved?
A: It was. Factrel (approved 1982) and Lutrepulse (approved 1989) were FDA-approved human gonadorelin products, but both are listed as discontinued. The gonadorelin products with current US labels are veterinary drugs for cattle.
Q: Does gonadorelin preserve fertility on TRT?
A: It has not been tested for that. We found no published or registered trial of gonadorelin alongside testosterone therapy as of November 12, 2026. Pulsatile gonadorelin by pump does restore sperm production in men born without a GnRH signal, but that is a different situation. hCG has direct, though limited, evidence for preserving sperm production during TRT.
Q: Is gonadorelin the same as hCG?
A: No. Gonadorelin acts on the pituitary, which then releases LH and FSH. hCG acts like LH directly on the testes. That means hCG works even when the pituitary is suppressed by testosterone therapy, while gonadorelin depends on the pituitary responding.
Q: Why does gonadorelin need to be given in pulses?
A: Because the pituitary responds to GnRH in bursts. A 1978 study showed hourly pulses restored hormone release in monkeys, while a constant infusion did not and could switch the pituitary off. Long-acting GnRH drugs like leuprolide use that shut-off effect on purpose.
Q: What are the side effects of gonadorelin?
A: In fertility studies, allergic reactions were the most notable problem, and they occurred mainly with GnRH therapy. Severe anaphylaxis has been reported after an intravenous test dose. Long-term safety data for self-injected or compounded products do not exist.
Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202:631-633. PubMed 100883
Wei C, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile GnRH therapy versus gonadotropin therapy: a systematic review and meta-analysis. World J Mens Health. 2021;39:654-665. PubMed 32777865
Mao JF, et al. Pulsatile GnRH therapy is associated with earlier spermatogenesis compared to combined gonadotropin therapy in patients with congenital hypogonadotropic hypogonadism. Asian J Androl. 2017;19:680-685. PubMed 28051040
Quaas P, et al. Use of pulsatile GnRH in patients with functional hypothalamic amenorrhea results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. J Assist Reprod Genet. 2022;39:2729-2736. PubMed 36378460
Filicori M, Cognigni GE. Ovulation induction with pulsatile gonadotropin releasing hormone: missing in action. Fertil Steril. 2018;109:621-622. PubMed 29653714
Hsieh TC, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189:647-650. PubMed 23260550
Naelitz BD, et al. Testosterone replacement therapy and spermatogenesis in reproductive age men. Nat Rev Urol. 2025;22:703-719. PubMed 40346275
Hochu G, et al. Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies. Transl Androl Urol. 2025;14:3975-3987. PubMed 41522318
Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423-432. PubMed 29601923
Vasylieva V, et al. Peptides in urology and sexual medicine: a narrative review. Sex Med Rev. 2026;14:qeag078. PubMed 42862021
Akın O, et al. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. J Pediatr Endocrinol Metab. 2015;28:1387-1389. PubMed 26197466
Seo JH, et al. Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys? Ann Pediatr Endocrinol Metab. 2025;30:278-280. PubMed 41207293
ClinicalTrials.gov searches for "gonadorelin" and "gonadorelin AND testosterone," November 12, 2026
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.
